



RESEARCH OPPORTUNITY

NAMI is committed to ensuring that the most effective treatments for mental illness are available to those who need them. Determining which treatments are most effective requires research.

When NAMI learns of new studies by physicians and other scientists involving new treatment methods, such as psychotherapies, medications, methods of medication delivery, etc. we become excited. That excitement comes from knowing that scientists continue to learn more about mental illness and look for ways to improve the lives of those affected by it. When NAMI is approached to be involved in research of any type, at any level, we take it very seriously. NAMI's Chief Medical Officer Dr. Ken Duckworth and National Director of Research and Quality Assurance Dr. Teri Brister thoroughly review the research protocols and methodology and the documentation that the study has been approved an Institutional Review Board (IRB) to assure the safety of those involved.

NAMI does not accept financial compensation for recruiting clinical trial participants. NAMI also does not endorse any products or treatments. We share these research opportunity notices with you, our field leaders, to distribute at your discretion if you believe that members of your community may be interested in participating in these trials.

If you have questions about research at NAMI, please visit [NAMI.org/research](https://www.nami.org/research) or email us at research@nami.org.

WHAT IS THE STUDY?

The Juniper study is a clinical trial to test the safety, efficacy and tolerability of centanafadine to treat major depressive disorder (MDD) in adults who have not responded to other treatment options. This is a randomized, double-blind study; some participants will be given centanafadine and others will be given a placebo. Researchers will be assessing the effectiveness of the investigational medication on its own and used in conjunction with escitalopram (Lexapro). Participation includes a screening period (up to 28 days), a 6-week trial period, and a 1-week follow-up period.

WHO CAN PARTICIPATE?

Individuals may be eligible for this study if they:

- Are 18 to 65 years old
- Have a diagnosis of major depressive disorder
- Have tried at least 1 but no more than 3 medication options for depression, with inadequate response

Note: Additional inclusion and exclusion criteria apply.

The researchers are seeking to screen 650 people and enroll 336 participants in the clinical trial.

WHERE IS THE STUDY TAKING PLACE?

This is a national study that is taking place at sites in the following states: Arizona, California, Florida, Georgia, Idaho, Illinois, Louisiana, Mississippi, New York, Ohio, Oregon, Pennsylvania, Texas, Utah, Vermont and Washington.

HOW DO I LEARN MORE?

The study poster includes additional information. If you have questions or would like more information, please visit the study listing on ClinicalTrials.gov [here](#). To complete the pre-screening survey, please visit the study website [here](#) and click the "Join us" button.